Longvida® Safety

Longvida® has been self-affirmed GRAS since 2012 and has been extensively investigated for its efficacy and safety in multiple human clinical trials, animal studies, and in in vitro experimental studies.

Gota et al (2010) investigated the pharmacokinetics of Longvida® compared to 95% standard curcuminoids in a crossover, double-blind, comparative pharmacokinetic analysis in healthy adult human subjects. In these healthy subjects, the mean peak concentration of curcumin (Cmax) achieved from dosing 650mg of Longvida® SLCP was 22.43 ng/mL, whereas plasma curcumin from dosing an equal quantity of unformulated 95% curcuminoids extract was not detected (<1 ng/ml). In the same study, administration of Longvida® in oral dosages of 2000mg, 3000mg, and 4000mg (containing 400-600mg of curcumin, respectively), with 8oz of water to osteosarcoma patients showed high plasma concentrations and dose-related AUCs. Overall, good tolerability was noted in both healthy and osteosarcoma groups.

Dadhaniya et al (2011) investigated both acute toxicity and 90-day sub-chronic toxicity of Longvida® in accordance with OECD guidelines. Terminal necropsy did not reveal any treatment-related gross or histopathological findings. Based on the results of this study, the NOAEL (no observed adverse effect level) for Longvida® was determined to be 720mg/kg bw/day, the highest dose tested (Dadhaniya et al, 2011).

In human clinical studies on Longvida® using 400mg dose (Scholey et al, 2019; McFarlin et al, 2016; Cox et al, 2014; DiSilvestro et al, 2012) supplementation of Longvida for one to 12 weeks has been found safe and well tolerated.

Further, several clinical studies have examined Longvida® at a daily dose of 2000mg+ (Hazarey et al, 2015; Santos-Parker et al, 2017; and others) and have notated that Longivda was safe and well tolderated.

In one double-blind, placebo-controlled human clinical study in healthy middle-aged and older adults (n=20; active and n= 19; placebo), Longvida® was found to be safe after administration of 2000mg/day dose for 12 weeks (Santos-Parker et al, 2017).

Additionally, there are several ongoing studies using Longvida® in different types of populations and so far we have not received any adverse event report from the investigators. This further supports the safety of Longvida®.

Longvida® contains the natural antioxidant curcumin, optimized by SLCP™ technology for maximum bioavailability into blood and target tissues. It supplies significant levels of free (not glucuronidated or inactivated) curcumin.

Contact us for more information.